Business Wire

Highly positive FM71 Phase 3 study results with all primary and secondary endpoints achieved, MED3000 remains on track to submit for FDA marketing authorization

Using the well-established Self Esteem and Relationship (SEAR) questionnaire, it was determined that at week 24, 85.4% of MED3000 users felt that sex could be spontaneous (Includes: Always/Almost ...
Healio

Topical gel for erectile dysfunction shows promise in phase 3 trial

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In a confirmatory study, MED3000 was associated with ...
Yahoo Finanzas

US FDA Grants for Over-the-Counter Marketing Authorization to Futura for Fast-Acting Topical Gel, MED3000, to Treat Erectile Dysfunction

- Company also announced that it raised proceeds of £4,375,000 to fund future commercialization of MED3000 via a warrant exercise by a large institutional shareholder - GUILDFORD, England, June 12, ...
FiercePharma

Futura's topical erectile dysfunction therapy hits phase 3 goal, igniting race to FDA

Futura Medical has reported phase 3 data on its topical erectile dysfunction treatment MED3000, teeing it up to file for FDA approval of the therapy as an over-the-counter medicine by the end of the ...
MedPage Today

FDA OKs Over-the-Counter Gel for Erectile Dysfunction

The FDA has granted over-the-counter marketing authorization to MED3000 (Eroxon), the first nonprescription topical gel for treating erectile dysfunction (ED) in men age 22 and older, maker Futura ...